In addition, the combination of cisplatin and PD-L1 inhibitors led to a notable decrease in tumor size in a murine lung cancer model and prolonged the survival tumor-bearing mice compared to anti-PD-L1 monotherapy [166]. This evidence concerns the gene CD274 and lung carcinoma.